Cargando…

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

BACKGROUND: The combination of infliximab and immunosuppressant therapy is a standard management strategy for patients with Crohn's disease. Concerns regarding the implications of long-term combination therapy provided the rationale for a formal clinical trial of treatment de-escalation. Our ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Louis, Edouard, Resche-Rigon, Matthieu, Laharie, David, Satsangi, Jack, Ding, Nik, Siegmund, Britta, D'Haens, Geert, Picon, Laurence, Bossuyt, Peter, Vuitton, Lucine, Irving, Peter, Viennot, Stephanie, Lamb, Christopher A, Pollok, Richard, Baert, Filip, Nachury, Maria, Fumery, Mathurin, Gilletta, Cyrielle, Almer, Sven, Ben-Horin, Shomron, Bouhnik, Yoram, Colombel, Jean-Frederic, Hertervig, Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908559/ https://www.ncbi.nlm.nih.gov/pubmed/36640794 http://dx.doi.org/10.1016/S2468-1253(22)00385-5

Ejemplares similares

Preoperative Predictors of Neoplasia in Patients Undergoing Small Bowel Resection for Complicated Crohn’s Disease: A Multicentre Case-Control Study
por: Chappe, Capucine, et al.
Publicado: (2023)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022)

Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2022)

Su1499: IMMUNOMODULATORS ARE PROTECTIVE AGAINST SEVERE COVID 19: RESULTS FROM A LARGE MULTICENTRE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
por: Vuitton, Lucine, et al.
Publicado: (2022)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study
por: Amiot, Aurelien, et al.
Publicado: (2022)

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
por: Bouhnik, Yoram, et al.
Publicado: (2018)

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
por: D’Haens, Geert, et al.
Publicado: (2023)

Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

A plea for the pathogenic role of immune complexes in severe Covid-19
por: Vuitton, Dominique A., et al.
Publicado: (2020)

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
por: Colombel, Jean-Frédéric, et al.
Publicado: (2020)

Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study
por: Reinisch, Walter, et al.
Publicado: (2020)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

Non-surgical and non-chemical attempts to treat echinococcosis: do they work?
por: Tamarozzi, Francesca, et al.
Publicado: (2014)

Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn’s Disease: A Pilot Study (ACROHNEM)
por: Capron, Monique, et al.
Publicado: (2019)

Inflammatory Bowel Disease and the SARS-CoV-2 Pandemic: More Speed, Less Haste
por: Gower-Rousseau, Corinne, et al.
Publicado: (2021)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Acute Pancreatitis Occurring after Pamidronate Infusions in Two Patients with Spondyloarthritis
por: Toussirot, Éric, et al.
Publicado: (2013)

Next-Generation Therapeutics for IBD
por: Löwenberg, Mark, et al.
Publicado: (2015)

Managing complex perianal disease after anti-TNF failure: Where to go next?
por: Yzet, Clare, et al.
Publicado: (2022)

Beyond borders: Do geographic correlations suggest shared environmental factors in inflammatory bowel diseases, Hodgkin lymphoma, and multiple sclerosis
por: Fay, Shmuel, et al.
Publicado: (2023)

Evaluating mortality in intensive care units: contribution of competing risks analyses
por: Resche-Rigon, Matthieu, et al.
Publicado: (2006)

Early non-invasive ventilation for acute respiratory failure in immunocompromised patients (IVNIctus): study protocol for a multicenter randomized controlled trial
por: Lemiale, Virginie, et al.
Publicado: (2014)

Evaluation of the Propensity score methods for estimating marginal odds ratios in case of small sample size
por: Pirracchio, Romain, et al.
Publicado: (2012)

Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
por: Kim, HoUng, et al.
Publicado: (2021)

rs2476601 polymorphism in PTPN22 is associated with Crohn’s disease but not with ulcerative colitis: a meta-analysis of 16,838 cases and 13,356 controls
por: Hedjoudje, Abdellah, et al.
Publicado: (2017)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Long-term Temporal Stability of Peripheral Blood DNA Methylation Profiles in Patients With Inflammatory Bowel Disease
por: Joustra, Vincent, et al.
Publicado: (2022)

Therapeutic drug monitoring in inflammatory bowel disease
por: Kopylov, Uri, et al.
Publicado: (2014)

Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
por: Ben-Horin, Shomron, et al.
Publicado: (2015)

Curcumin-QingDai Combination as Treatment for Moderate-Severe Ulcerative Colitis
por: Ben-Horin, Shomron, et al.
Publicado: (2022)

Do simple screening statistical tools help to detect reporting bias?
por: Pirracchio, Romain, et al.
Publicado: (2013)

Simple screening statistical tools to detect reporting bias: when should we ask for raw data?
por: Pirracchio, Romain, et al.
Publicado: (2013)

Larval Echinococcus multilocularis infection reduces dextran sulphate sodium‐induced colitis in mice by attenuating T helper type 1/type 17‐mediated immune reactions
por: Wang, Junhua, et al.
Publicado: (2017)

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report
por: Strik, Anne S., et al.
Publicado: (2019)

Systematic Review and Meta-analysis of Peripheral Blood DNA Methylation Studies in Inflammatory Bowel Disease
por: Joustra, Vincent, et al.
Publicado: (2022)

Heckman imputation models for binary or continuous MNAR outcomes and MAR predictors
por: Galimard, Jacques-Emmanuel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8d2pbjgpgbl3b3ge8j9hnqmf2t